News Ratings For Satsuma Pharmaceuticals Daily News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from News ratings for satsuma pharmaceuticals daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In News Ratings For Satsuma Pharmaceuticals Daily Today - Breaking & Trending Today

Ken Takanashi Purchases 22,053,581 Shares of Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Stock

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi purchased 22,053,581 shares of the business’s stock in a transaction that occurred on Tuesday, June 6th. The stock was bought at an average price of $0.91 per share, for a total transaction of $20,068,758.71. Following the purchase, the director now directly owns 24,847,694 shares in […] ....

United States , Ken Takanashi , News Ratings For Satsuma Pharmaceuticals Daily , Satsuma Pharmaceuticals , America Corp , Institutional Trading Of Satsuma Pharmaceuticals , Satsuma Pharmaceuticals Stock Performance , Investment Advisers , Satsuma Pharmaceuticals Inc , Millennium Management , Get Rating , Director Ken Takanashi , Sigma Advisers , Two Sigma Investments , Sigma Investments , Satsuma Pharmaceuticals Daily , Nasdaq Stsa , Insider Trading , Nsider Trades ,

New York Mortgage Trust, Inc. (NASDAQ:NYMTN) Declares Quarterly Dividend of $0.50

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) Director Ken Takanashi acquired 22,053,581 shares of Satsuma Pharmaceuticals stock in a transaction dated Tuesday, June 6th. The shares were purchased at an average price of $0.91 per share, with a total value of $20,068,758.71. Following the acquisition, the director now owns 24,847,694 shares of the company’s stock, […] ....

Ken Takanashi , Satsuma Pharmaceuticals Stock Performance , Institutional Investors Weigh In On Satsuma Pharmaceuticals , Satsuma Pharmaceuticals , Satsuma Pharmaceuticals Company Profile , Capital Management , Vanguard Group Inc , Walleye Capital , Satsuma Pharmaceuticals Inc , Renaissance Technologies , News Ratings For Satsuma Pharmaceuticals Daily , Get Rating , Director Ken Takanashi , Sigma Investments , Satsuma Pharmaceuticals Daily ,

Satsuma Pharmaceuticals (NASDAQ:STSA) & Aridis Pharmaceuticals (NASDAQ:ARDS) Head-To-Head Analysis

Satsuma Pharmaceuticals (NASDAQ:STSA – Get Rating) and Aridis Pharmaceuticals (NASDAQ:ARDS – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, analyst recommendations and valuation. Earnings & Valuation This table compares Satsuma Pharmaceuticals and […] ....

Los Gatos , United States , South San Francisco , Ericj Patzer , Vul Truong , Satsuma Pharmaceuticals Inc , Aridis Pharmaceuticals Inc , News Ratings For Satsuma Pharmaceuticals Daily , Satsuma Pharmaceuticals , Aridis Pharmaceuticals , Get Rating , Aridis Pharmaceutical , Given Aridis Pharmaceutical , Satsuma Pharmaceuticals Daily , Nasdaq Stsa , Stock Comparison , Stock Analysis ,

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Short Interest Down 58.0% in May

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the recipient of a large decrease in short interest during the month of May. As of May 15th, there was short interest totalling 130,100 shares, a decrease of 58.0% from the April 30th total of 310,100 shares. Approximately 0.5% of the shares of the stock are sold […] ....

Satsuma Pharmaceuticals Company Profile , Institutional Investors Weigh In On Satsuma Pharmaceuticals , Satsuma Pharmaceuticals Inc , Virtu Financial , Barclays Plc , Satsuma Pharmaceuticals Trading Down , Nan Fung Group Holdings Ltd , Satsuma Pharmaceuticals , News Ratings For Satsuma Pharmaceuticals Daily , Millennium Management , Get Rating , Fung Group Holdings Ltd , Street Corp , Pharmaceuticals Trading Down , Satsuma Pharmaceuticals Daily , Nasdaq Stsa ,

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA) Short Interest Update

Satsuma Pharmaceuticals, Inc. (NASDAQ:STSA – Get Rating) was the target of a large decline in short interest in May. As of May 15th, there was short interest totalling 130,100 shares, a decline of 58.0% from the April 30th total of 310,100 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is […] ....

Satsuma Pharmaceuticals , Jpmorgan Chase Co , Satsuma Pharmaceuticals Stock Down , Walleye Capital , News Ratings For Satsuma Pharmaceuticals Daily , Dimensional Fund Advisors , Satsuma Pharmaceuticals Inc , Get Rating , Fund Advisors , Street Corp , Pharmaceuticals Stock Down , Satsuma Pharmaceuticals Daily , Nasdaq Stsa ,